Healthcare Sector Announced Financial Results - Research Report on Ligand, Auxilium, STERIS, USANA, and Cardiovascular Systems
NEW YORK, November 4, 2013 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
Today, Analysts' Corner announced new research reports highlighting Ligand Pharmaceuticals Incorporated (NASDAQ: LGND), Auxilium Pharmaceuticals Inc. (NASDAQ: AUXL), STERIS Corp. (NYSE: STE), USANA Health Sciences Inc. (NYSE: USNA), and Cardiovascular Systems Inc. (NASDAQ: CSII). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Ligand Pharmaceuticals Incorporated Research Report
On October 30, 2013, Ligand Pharmaceuticals Incorporated (Ligand) reported its financial results for Q3 2013. Total revenue increased 104.0% YoY to $13.0 million. Net income was $2.0 million or $0.09 per diluted share, compared to net loss of $194,000 or $0.01 per diluted share in Q3 2012. Commenting on the results, President and CEO John Higgins said, "Ligand continued to post significant revenue growth and to demonstrate the strength of its business model during the third quarter. Recently, two significant partnered programs received regulatory approvals. Pfizer's Duavee™ received FDA approval for the treatment of moderate-to-severe vasomotor symptoms associated with menopause and the prevention of postmenopausal osteoporosis. GlaxoSmithKline's Revolade (Promacta) received European Commission marketing approval to treat low platelet counts in patients with chronic hepatitis C infection. These are exciting developments, along with portfolio additions and other late-stage advancements that reinforce the long-term potential of Ligand's partnered portfolio." The Full Research Report on Ligand Pharmaceuticals Incorporated - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/3b8d_LGND]
Auxilium Pharmaceuticals Inc. Research Report
On October 24, 2013, Auxilium Pharmaceuticals Inc. (Auxilium) announced that the Company will release its financial results for Q3 2013 on November 6, 2013. Auxilium reported that it will also conduct a conference call on the same day at 10:00 a.m. ET, to discuss results and highlights of Q3 2013. The Full Research Report on Auxilium Pharmaceuticals Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/86a4_AUXL]
STERIS Corp. Research Report
On October 30, 2013, STERIS Corp. (STERIS) reported its financial results for Q2 FY 2014 (period ended September 30, 2013). Revenue increased 14.2% YoY to $383.8 million. Net income was $29.7 million or $0.50 per diluted share, compared to net income of $40.1 million or $0.68 per diluted share in Q2 FY 2013. Commenting on the results, President and CEO Walt Rosebrough said, "We are pleased that our performance returned to expectations this quarter, reflecting the continued growth in our end-markets and success with new products. With solid organic growth across all segments and strong backlog, we have confidence in our ability to produce a strong second half of the year. Due largely to the timing of investments for our in-sourcing projects, we now anticipate that earnings will be in the lower half of our previously provided range of $2.47 to $2.60 for the full fiscal year." The Full Research Report on STERIS Corp. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/8e31_STE]
USANA Health Sciences Inc. Research Report
On October 22, 2013, USANA Health Sciences Inc. (USANA) reported its financial results for Q3 FY 2013 (period ended September 28, 2013). Net sales increased 5.2% YoY to $173.7 million. Net earnings were $16.8 million or $1.16 per diluted share, compared to $17.5 million or $1.18 per diluted share in Q3 FY 2012. Commenting on the results, USANA's CEO Dave Wentz said, "During the third quarter, we implemented a number of strategic initiatives at our 2013 International Convention. These initiatives, which include price reductions and enhancements to our Associate compensation plan, are intended to drive long-term, sustainable customer growth for USANA." The Full Research Report on USANA Health Sciences Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/ee40_USNA]
Cardiovascular Systems Inc. Research Report
On October 30, 2013, Cardiovascular Systems Inc. (Cardiovascular Systems) reported its financial results for Q1 FY 2014 (period ended September 30, 2013). Revenues increased 27.8% YoY to $29.8 million. Net loss was $7.3 million or $0.29 per diluted share, compared to net loss of $5.2 million or $0.26 per diluted share in Q1 FY 2013. Commenting on the results, President and CEO David L. Martin said, "Strong adoption of our Stealth 360 in the expanding $2.0 billion U.S. PAD market continued to drive revenue growth in the first quarter. Physicians are embracing our easy-to-use technology that provides a superior solution to treat arterial calcium. Calcium is present in approximately 65 percent of all PAD arteries treated and in nearly 80 percent of the small arteries treated below the knee." The Full Research Report on Cardiovascular Systems Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/11b9_CSII]
EDITOR NOTES:
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to making mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
- For any urgent concerns or inquiries, please contact us at [email protected].
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts' Corner
Share this article